Article Versions Notes

Friebel J, Moritz E, Witkowski M, Jakobs K, Strässler E, Dörner A, Steffens D, Puccini M, Lammel S, Glauben R, et al. Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation. Cells. 2021; 10(12):3517. https://doi.org/10.3390/cells10123517

Friebel, Julian, Eileen Moritz, Marco Witkowski, Kai Jakobs, Elisabeth Strässler, Andrea Dörner, Daniel Steffens, Marianna Puccini, Stella Lammel, Rainer Glauben, and et al. 2021. "Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation" Cells 10, no. 12: 3517. https://doi.org/10.3390/cells10123517

Friebel, J., Moritz, E., Witkowski, M., Jakobs, K., Strässler, E., Dörner, A., Steffens, D., Puccini, M., Lammel, S., Glauben, R., Nowak, F., Kränkel, N., Haghikia, A., Moos, V., Schutheiss, H. -P., Felix, S. B., Landmesser, U., Rauch, B. H., & Rauch, U. (2021). Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation. Cells, 10(12), 3517. https://doi.org/10.3390/cells10123517